Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-6ad927719fc570edf8a72cacebe37a51"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-6ad927719fc570edf8a72cacebe37a51"/>
<resource>
<Composition>
<id value="composition-en-6ad927719fc570edf8a72cacebe37a51"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-6ad927719fc570edf8a72cacebe37a51"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-6ad927719fc570edf8a72cacebe37a51</b></p><a name="composition-en-6ad927719fc570edf8a72cacebe37a51"> </a><a name="hccomposition-en-6ad927719fc570edf8a72cacebe37a51"> </a><a name="composition-en-6ad927719fc570edf8a72cacebe37a51-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1641/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - prehevbri</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1641/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp6ad927719fc570edf8a72cacebe37a51"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - prehevbri"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What PreHevbri is and what it is used for</li><li>What you need to know before you receive PreHevbri</li><li>How PreHevbri is given</li><li>Possible side effects</li><li>How to store PreHevbri</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What prehevbri is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What prehevbri is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>PreHevbri is a vaccine which prevents infection caused by the hepatitis B virus. It is used in adults to protect from all known types of hepatitis B virus.</p><p>PreHevbri may also protect against hepatitis D which can only occur in people who have hepatitis B infection.</p><p>What is hepatitis B</p><ul><li>Hepatitis B is an infectious illness of the liver caused by a virus. Hepatitis B virus infection can cause serious liver problems such as cirrhosis (scarring in the liver) or liver cancer.</li><li>Some people infected with the hepatitis B virus become carriers, which means that they may not feel ill but continue to have the virus in their body and they can still infect other people.</li><li>The disease spreads by the hepatitis B virus entering the body through contact with an infected person s body fluids, such as in the vagina, blood, semen, or spit (saliva). A mother who is a carrier of the virus can also pass the virus to her baby at birth.</li><li>The main signs of the illness include mild signs of flu (such as headache and fever, feeling very tired, dark urine, pale stools [faeces], and yellowing of the skin and eyes [jaundice]). However, some people with hepatitis B do not look or feel ill.</li></ul><p>How PreHevbri works</p><p>When a person is given the PreHevbri vaccine, it helps the body s natural defence system (immune system) produce specific protection (antibodies) against the hepatitis B virus.</p><ul><li>PreHevbri contains a substance (called an adsorbent ) which improves the body s production of antibodies and makes the protection last for longer.</li><li>A course of three injections of PreHevbri is required to provide full protection against hepatitis B.</li><li>PreHevbri is not used to treat a person who is already infected with the hepatitis B virus including anyone who has previously been infected and who is now a carrier of the virus.</li><li>Prehevbri is a 3-antigenic vaccine, which contains small amounts of the three antigens (pre-S1, pre-S2, S) from the outer coating of the hepatitis B virus. This outer coating is not infectious and cannot make you ill.</li></ul></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take prehevbri"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take prehevbri"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You must NOT receive PreHevbri:</p><ul><li>if you are allergic to the active substance or any of the other ingredients of this vaccine<br/>(listed in section 6). Signs of an allergic reaction may include breathing difficulty, swelling, light-headedness, fast heartbeat, sweating, and loss of consciousness.</li><li>if you have ever previously had a sudden, life-threatening allergic reaction to any vaccine against hepatitis B.</li></ul><p>You must not receive PreHevbri if either of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before receiving PreHevbri.</p><p>Warnings and precautions</p><ul><li>Your doctor, pharmacist or nurse will make sure that appropriate medical treatment is readily available in case you should develop a sudden and rare anaphylactic reaction (a very severe allergic reaction with symptoms such as breathing difficulty, swelling, light-headedness, fast heartbeat, sweating, and loss of consciousness) after you have been given the vaccine. This reaction may occur when any vaccine is injected, including PreHevbri. Seek urgent medical attention if you develop any of these symptoms after you are given the injectionas this could be a life-threatening allergic reaction.</li><li>Fainting can occur following, or even before, any needle injection, therefore tell the doctor, pharmacist or nurse if you fainted with a previous injection.</li><li>If you are ill with a high fever, tell your doctor, pharmacist or nurse as they may delay the vaccination until you are feeling better. A minor infection such as a cold should not be a problem, but your doctor, pharmacist or nurse will decide if you could still be vaccinated.</li><li>If you have low blood platelets or any blood-clotting disorders, then bleeding or bruising may occur after you are given the injection. Tell your doctor, pharmacist or nurse if you have any of these conditions.</li><li>PreHevbri may not prevent hepatitis B infection if you already have an unrecognised hepatitis B infection at the time of vaccine administration.</li><li>As with any vaccine, PreHevbri may not protect all people who are vaccinated.</li><li>PreHevbri does not protect you against other liver infections such as hepatitis A, C, and E.</li><li>If you are on dialysis for a kidney problem or if you have a weakened immune system your doctor may need to do a blood test to check if the vaccination has worked well enough to protect you against hepatitis B.</li></ul><p>If you have any concerns or you are not sure about any of the above, talk to your doctor, pharmacist or nurse before receiving PreHevbri.</p><p>Children and adolescents PreHevbri has not been fully tested in children under 18 years of age, it should not be used in this age group.</p><p>Other medicines and PreHevbri Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines, including any other vaccine.</p><p>In addition to PreHevbri, you may be given an injection of hepatitis B 'immuno-globulins'. This will give you immediate short-term protection against hepatitis B infection. If this happens your doctor, pharmacist or nurse will make sure that the two injections are given in different parts of the body.</p><p>Pregnancy and breast-feeding<br/>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before being given this vaccine.</p><p>It is unknown whether PreHevbri is excreted in human milk. A risk to the suckling child cannot be excluded. Discuss with your doctor or nurse whether the risks and benefits of breast-feeding your child outweigh the benefit of vaccination and whether you should stop breast-feeding.</p><p>Driving and using machines PreHevbri is unlikely to have any effect on the ability to drive and use machines. If you feel tired, or have a headache or feel dizzy after having the vaccine, do not drive or use any machines until you feel well again.</p><p>PreHevbri contain sodium and potassium This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. that is to say is essentially 'sodium-free .</p><p>This vaccine contains less than 1 mmol potassium (39 mg) per dose, i.e. that is to say is essentially potassium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take prehevbri"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take prehevbri"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>PreHevbri will be given to you as an injection by a doctor, pharmacist or nurse. The vaccine will usually be injected into a muscle in your upper arm.</p><p>You will be given a total of three injections. Each injection will be given on separate visits:</p><ul><li>1st injection: on a date agreed with your doctor, pharmacist or nurse;</li><li>2nd injection: 1 month after the 1st injection;</li><li>3rd injection: 6 months after the 1st injection.</li></ul><p>The recommended dose for each injection is 10 micrograms (1 mL of suspension for injection ).</p><p>If you forget a scheduled dose of PreHevbri If you miss a scheduled dose, talk to your doctor, pharmacist or nurse to arrange another visit to receive the missed dose.</p><p>Make sure you receive the complete course of three injections or you may not be fully protected.</p><p>If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all vaccines, this vaccine can cause side effects, although not everybody gets them.</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>feeling very tired;</li><li>pain or tenderness at the injection site;</li><li>itching at the injection site;</li><li>muscle pain;</li><li>headache.</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>diarrhoea;</li><li>feeling or being sick;</li><li>stomach pain;</li><li>redness, bruising or swelling at the injection site;</li><li>rash;</li><li>dizziness;</li><li>joint pain;</li><li>fever.</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>swollen lymph nodes;</li><li>hives or itchy skin;</li><li>flushing or hot flushes.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this vaccine.</p></div>
</text>
</section>
<section>
<title value="5. How to store prehevbri"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store prehevbri"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this vaccine out of the sight and reach of children.</p><p>Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.</p><p>Store vials in a refrigerator (2 C to 8 C). Store in the original package in order to protect from light. Do not freeze.</p><p>Do not throw away any vaccines via wastewater. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What PreHevbri contains</p><p>One dose (1 mL) contains:</p><ul><li>Active substances: 10 micrograms of hepatitis B surface antigens (S [83%], pre-S2 [11%] and pre-S1 [6%]) 1, 2</li></ul><p>1 Adsorbed on 500 micrograms of Al3+ as aluminium hydroxide, hydrated</p><p>2 Produced in Chinese Hamster Ovary cells by recombinant DNA technology</p><ul><li>The other ingredients are sodium chloride, potassium chloride, disodium phosphate dodecahydrate, potassium dihydrogen phosphate, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment), water for injections.</li></ul><p>What PreHevbri looks like and contents of the pack PreHevbri is a clear, colourless suspension with a fine white deposit. When the vial is shaken the suspension forms a slightly white opaque suspension.</p><p>PreHevbri is supplied in vials containing 1 mL. Each vial is for single use only.</p><p>Packs of 1 or 10 single-dose vials are available.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>VBI Vaccines B.V. Delflandlaan 1<br/>Queen s Tower, No. 1062EA Amsterdam Netherlands</p><p>Manufacturer MIAS Pharma Limited Suite 1, First Floor, Stafford House Strand Road Portmarnock, D13 WCIreland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Valneva France SAS France T l/Tel: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a></p><p>Lietuva VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>VBI Vaccines B.V. Netherlands Te .: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Luxembourg/Luxemburg VBI Vaccines B.V. Netherlands T l/Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a><br/>esk republika VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Magyarorsz g VBI Vaccines B.V. Netherlands Tel.: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> Danmark Valneva Sweden AB Sweden Tlf: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a></p><p>Malta VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> Deutschland VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Nederland Valneva France SAS France Tel: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a> Eesti VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Norge Valneva Sweden AB Sweden Tlf: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a></p><p>VBI Vaccines B.V. Netherlands : +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>sterreich VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> Espa a VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Polska VBI Vaccines B.V. Netherlands Tel.: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> France VBI Vaccines B.V. Netherlands T l: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Portugal VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> Hrvatska VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Rom nia VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> Ireland VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Slovenija VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> sland VBI Vaccines B.V. Netherlands S mi: +31 20 2997Netfang: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Slovensk republika VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a><br/>Italia VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Suomi/Finland Valneva Sweden AB Sweden Puh/Tel: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a></p><p>VBI Vaccines B.V. Netherlands : +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a></p><p>Sverige Valneva Sweden AB Tel: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a> Latvija VBI Vaccines B.V. Netherlands Tel: +31 20 2997e-mail: <a href="mailto:medinfo@vbivaccines.com">medinfo@vbivaccines.com</a> United Kingdom (Northern Ireland) Valneva Austria GmbH Austria Tel: +43 120620 1e-mail: <a href="mailto:medinfo@valneva.com">medinfo@valneva.com</a></p><p>This leaflet was last revised in MM/YYYY.</p><p>Other sources of information</p><p>Detailed information on this vaccine is available on the European Medicines Agency web site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p><hr/><p>The following information is intended for healthcare professionals only:</p><p>Storage</p><ul><li>Vials should be stored in a refrigerator (2 C to 8 C) ).Store in the original carton in order to protect from light.</li><li>Do not freeze .</li></ul><p>Preparation</p><ul><li>The vaccine should be used under aseptic conditions.</li><li>The suspension is slightly white opaque when mixed. Upon settling, the solution is clear and colourless with a white deposit.</li><li>The suspension should be visually inspected prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine.</li><li>The vial should be shaken well prior to administration.</li></ul><p>Administration</p><ul><li>PreHevbri should be injected intramuscularly into the deltoid muscle.</li><li>Do not inject PreHevbri into the gluteal muscle, or intradermally or intravascularly.</li><li>Each vial is for single use only.</li><li>PreHevbri must not be mixed with other medicinal products.</li></ul><p>Disposal Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp6ad927719fc570edf8a72cacebe37a51"/>
<resource>
<MedicinalProductDefinition>
<id value="mp6ad927719fc570edf8a72cacebe37a51"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp6ad927719fc570edf8a72cacebe37a51"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp6ad927719fc570edf8a72cacebe37a51</b></p><a name="mp6ad927719fc570edf8a72cacebe37a51"> </a><a name="hcmp6ad927719fc570edf8a72cacebe37a51"> </a><a name="mp6ad927719fc570edf8a72cacebe37a51-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1641/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: PreHevbri 10 micrograms suspension for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1641/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="PreHevbri 10 micrograms suspension for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
